Neuromuscular

Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.

Here's some of what is coming soon to NeurologyLive® this week.

Neurology News Network for the week ending January 17, 2025. [WATCH TIME: 4 minutes]

The therapy also received orphan drug designation from the FDA.

Paul Melmeyer, MPP, executive vice president, public policy and advocacy, Muscular Dystrophy Association, explains how adding Duchenne muscular dystrophy to the Recommended Unified Screening Panel reshapes early diagnosis, treatment timing, and family counseling.

Published phase 3 data in JAMA Neurology highlighted tofersen's potential to slow ALS progression and improve survival, marking a breakthrough in SOD1-ALS treatment.

In the middle of 2026, the company is planning to submit a BLA for RGX-202 via an accelerated approval pathway.

The European Commission approved Biogen’s high-dose nusinersen regimen for 5q SMA, supported by DEVOTE trial data showing significantly improved motor function with a safety profile consistent with the standard-dose regimen.

The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.

The research portfolio director at the Muscular Dystrophy Association spoke about ongoing advances in ALS research and how they may inform approaches to therapeutic development. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Annexon submitted an EMA marketing application for tanruprubart, a first-in-class C1q monoclonal antibody that showed faster and more complete recovery in Guillain-Barré syndrome patients across randomized trials.

Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, provided an outlook on the 2026 MDA meeting and what clinicians should look forward to in preparation.

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

The chief research officer of the Muscular Dystrophy Association outlined MDA’s growing focus on muscle regeneration research and explains why the 2026 MDA Conference is a must-attend meeting for clinicians. [WATCH TIME: 3 minutes]

Catch up on any of the neurology news headlines you may have missed in December 2025, compiled into 1 place by the NeurologyLive® team.

The chief research officer of the Muscular Dystrophy Association outlined emerging scientific priorities and community-driven initiatives shaping the 2026 MDA Clinical and Scientific Conference. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

ALS expert Sabrina Paganoni, MD, PhD, provided follow-up commentary on promising phase 1 data from the LUMINA trial testing Amylyx’s novel agent AMX0114 in patients with early-stage ALS.

Neurology News Network for the week ending January 3, 2025. [WATCH TIME: 4 minutes]

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

Here's some of what is coming soon to NeurologyLive® this week.

A look back at clinician-led features from 2025 that examine the questions, data, and decisions shaping neurologic care.